Li Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Wei has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Chong Chen
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication- Chun-Pu Zou
School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People’s Republic of China
1 shared publication - Hua Li
Department of Biology, School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People’s Republic of China
1 shared publication - Jing Hu
Preclinical Medicine College of Shanghai University of Traditional Chinese Medicine, 1200 Cailun Rd, Shanghai, 201203, P.R. China
1 shared publication - Shu-Hui Zhang
Department of Pathology, Shanghai University of Traditional Chinese Medicine Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai, China
1 shared publication - Siqi Zhang
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication
Latest Publications
- 8 August 2018
- Published by Wiley in Phytotherapy Research
- Vol. 32 (11) , 2155-2163
Phytochemistry, pharmacology, and clinical use of Panax notoginseng flowers buds
Panax notoginseng is a well‐known traditional Chinese medicine, and dried flower buds of P. notoginseng (FBP) have also been used as a medicine or tea for a long time. The pharmacological effects of FBP include antihypertensive, anticancer, hepatoprotective, and cardiovascular protective effects. The compounds in FBP include saponins, flavonoids, volatile oils, and polysaccharides. The total saponins are the principal bioactive components. In modern applications, FBP is used to treat hypertension and tinnitus. There have been many studies on FBP and its effects in recent years, and it has attracted much attention in the medical field. This review summarizes the chemical components, pharmacological action, and clinical uses of FBP comprehensively to provide the references of deeper studies.
- 8 August 2018
- Published by Wiley in Phytotherapy Research
- Vol. 32 (11) , 2155-2163
Phytochemistry, pharmacology, and clinical use of Panax notoginseng flowers buds
Panax notoginseng is a well‐known traditional Chinese medicine, and dried flower buds of P. notoginseng (FBP) have also been used as a medicine or tea for a long time. The pharmacological effects of FBP include antihypertensive, anticancer, hepatoprotective, and cardiovascular protective effects. The compounds in FBP include saponins, flavonoids, volatile oils, and polysaccharides. The total saponins are the principal bioactive components. In modern applications, FBP is used to treat hypertension and tinnitus. There have been many studies on FBP and its effects in recent years, and it has attracted much attention in the medical field. This review summarizes the chemical components, pharmacological action, and clinical uses of FBP comprehensively to provide the references of deeper studies.
- Open Access
- 1 July 2015
- Published by Springer Nature in Chinese Medicine
- Vol. 10 (1) , 15
Panax Notoginseng flower saponins (PNFS) inhibit LPS-stimulated NO overproduction and iNOS gene overexpression via the suppression of TLR4-mediated MAPK/NF-kappa B signaling pathways in RAW264.7 macrophages
Panax Notoginseng flower saponins (PNFS) are the main active component of Panax notoginseng (Burk) F. H. Chen flower bud (PNF) and possess significant anti-inflammatory efficacy. This study aims to explore the mechanisms underlying PNFS’ antiflammatory action in RAW264.7 macrophages. A cell counting kit-8 assay was used to determine the viability of RAW264.7 macrophages. Anti-inflammation effects of PNFS in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages were measured based on the detection of nitric oxide (NO) overproduction (Griess method, DAF-FM DA fluorescence assay and NO2 − scavenging assay), and interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha gene overexpression (real-time PCR and ELISA). Inducible nitric oxide synthase (iNOS) gene overexpression was determined by real-time PCR and western blotting. iNOS enzyme activity was also assayed. The mechanisms underlying the suppression of iNOS gene overexpression by PNFS were explored using real-time PCR and western blotting to assess mRNA and protein levels of components of the Toll-like receptor 4 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and nuclear factor-kappa B (NF-kappa B) signaling pathways. PNFS (50, 100, 200 μg/mL) significantly reduced LPS-induced overproduction of NO (P < 0.001, P < 0.001, P < 0.001) and IL-6 (P = 0.103, P < 0.001, P < 0.001), but did not affect TNF-alpha overproduction. PNFS (50, 100, 200 μg/mL) also markedly decreased LPS-activated iNOS (P < 0.001, P < 0.001, P < 0.001) and TLR4 gene overexpression (P = 0.858, P = 0.046, P = 0.005). Furthermore, treatment with PNFS (200 μg/mL) suppressed the phosphorylation of MAPKs including P38 (P = 0.001), c-Jun N-terminal kinase (JNK) (P = 0.036) and extracellular-signal regulated kinase (ERK) 1/2 (P = 0.021). PNFS (200 μg/mL) inhibited the activation of the NF-kappa B signaling pathway by preventing the phosphorylation of inhibitor of NF-kappa B alpha (I-kappa B alpha) (P = 0.004) and P65 (P = 0.023), but PNFS (200 μg/mL) could not activate the LPS-induced PI3K-Akt signaling pathway. PNFS significantly down-regulated iNOS gene overexpression and thereby decreased NO overproduction via the inhibition of TLR4-mediated MAPK/NF-kappa B signaling pathways, but not the PI3K/Akt signaling pathway.
- 1 July 2015
- Published by Springer Nature in Chinese Medicine
- Vol. 10 (1) , 15
Open AccessPanax Notoginseng flower saponins (PNFS) inhibit LPS-stimulated NO overproduction and iNOS gene overexpression via the suppression of TLR4-mediated MAPK/NF-kappa B signaling pathways in RAW264.7 macrophages
Panax Notoginseng flower saponins (PNFS) are the main active component of Panax notoginseng (Burk) F. H. Chen flower bud (PNF) and possess significant anti-inflammatory efficacy. This study aims to explore the mechanisms underlying PNFS’ antiflammatory action in RAW264.7 macrophages. A cell counting kit-8 assay was used to determine the viability of RAW264.7 macrophages. Anti-inflammation effects of PNFS in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages were measured based on the detection of nitric oxide (NO) overproduction (Griess method, DAF-FM DA fluorescence assay and NO2 − scavenging assay), and interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha gene overexpression (real-time PCR and ELISA). Inducible nitric oxide synthase (iNOS) gene overexpression was determined by real-time PCR and western blotting. iNOS enzyme activity was also assayed. The mechanisms underlying the suppression of iNOS gene overexpression by PNFS were explored using real-time PCR and western blotting to assess mRNA and protein levels of components of the Toll-like receptor 4 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and nuclear factor-kappa B (NF-kappa B) signaling pathways. PNFS (50, 100, 200 μg/mL) significantly reduced LPS-induced overproduction of NO (P < 0.001, P < 0.001, P < 0.001) and IL-6 (P = 0.103, P < 0.001, P < 0.001), but did not affect TNF-alpha overproduction. PNFS (50, 100, 200 μg/mL) also markedly decreased LPS-activated iNOS (P < 0.001, P < 0.001, P < 0.001) and TLR4 gene overexpression (P = 0.858, P = 0.046, P = 0.005). Furthermore, treatment with PNFS (200 μg/mL) suppressed the phosphorylation of MAPKs including P38 (P = 0.001), c-Jun N-terminal kinase (JNK) (P = 0.036) and extracellular-signal regulated kinase (ERK) 1/2 (P = 0.021). PNFS (200 μg/mL) inhibited the activation of the NF-kappa B signaling pathway by preventing the phosphorylation of inhibitor of NF-kappa B alpha (I-kappa B alpha) (P = 0.004) and P65 (P = 0.023), but PNFS (200 μg/mL) could not activate the LPS-induced PI3K-Akt signaling pathway. PNFS significantly down-regulated iNOS gene overexpression and thereby decreased NO overproduction via the inhibition of TLR4-mediated MAPK/NF-kappa B signaling pathways, but not the PI3K/Akt signaling pathway.